simvastatin in patients with UCB treated with RC identified no unexpected or unacceptable toxicity with the drug combination. Promising efficacy in decreasing PI3K/Akt/mTOR signaling was observed and trial enrollment continues.
INTRODUCTION AND OBJECTIVES: Cutaneous ureterostomy is an option for urinary diversion in selected patients, however stomal stenosis remains a limiting factor. To reduce the stoma related complications we have made two unique modifications of the conventional technique. We aim to present the technique and outcome of our "Smiley" cuteneous ureterostomy (SCU) and compared them with our pre-existing technique METHODS: Between September 2016 to May 2018, 12 patients had "SCU". End to side transuretero-ureterostomy was done and right ureter was taken out as ureterostomy (n[10). The first modification was the lateral location of the stoma, close to anterior axillary line instead of the more conventional medial location to keep the ureter straight and short. The second modification was to raise a wide based skin flap (base width w 4 cm) to cover half or more of the circumference of the stoma opening with the tip of the flap approximately four cm proximal to the ureteric margin at the angle of the spatulated site (smiley appearance) to prevent stomal stenosis (Figure 1,2) . Double J stents were placed for 2-4 weeks. Stoma related complications were compared with our preexisting published technique (https://www.ncbi.nlm.nih.gov/pubmed/29799401) RESULTS: Of the 12 patients (mean age 69.5þ5.5 yrs), 7 had radical cystectomy (T3 and T4 with or without lymphnodal metastasis) and one had radical cystectomy with left nephroureterectomy. Four had palliative cystectomy. Only one patient developed narrowing of the common ureteric channel proximal to the stoma following adjuvant radiotherapy. One patient expired in follow up with metastatic disease. Rest of the patients had well functioning stoma without need for any calibration or self dilatation with median follow up of 10.5 months (5-19 months). None of the patients had any problem related to ureterostomy bag application. This cohort had more than 90% complication free stoma as compared to our older published series with at least 25% reported major stoma related complications (p[0.04) CONCLUSIONS: "Smiley" cutaneous ureterostomy provides an excellent option for urinary diversion following radical cystectomy especially in cases of advanced disease, poor risk patients or in the setting of palliative cystectomy Source of Funding: None
MP38-12 LIPOSOMAL BUPIVACAINE (EXPARELÒ) ADMINISTRATION IN OPEN RADICAL CYSTECTOMY IS ASSOCIATED WITH DECREASED POST-OPERATIVE PAIN, LENGTH OF STAY, AND OPIOID USE
Carissa Chu*, Lauren Law, Lee-Lynn Chen, Candy Tsourounis, Kirsten Greene, Maxwell Meng, Sima Porten, San Francisco, CA INTRODUCTION AND OBJECTIVES: Liposomal bupivacaine (ExparelÒ, LB) is a slow-release, depofoam formulation indicated for subfascial infiltration at the incision to provide local analgesia up to 72 hours after surgery. Since November 2017, LB has replaced epidural analgesia in the enhanced recovery after surgery (ERAS) pathway for patients undergoing open radical cystectomy (RC) at UCSF. Reducing opioid exposure remains a high priority. Our aim was to perform an early assessment of clinical outcomes of LB in our ERAS pathway. Our hypothesis was that the use of LB would be associated with decreased post-operative pain scores, decreased opioid use, and shorter length of stay.
METHODS: A prospective cohort of consecutive patients undergoing RC on the ERAS pathway was compared to historical controls undergoing the same procedure. Prospective data collection began November 2017. Historical controls received epidural or patientcontrolled analgesia (PCA) from October 2016 to November 2017. Inclusion criteria included all patients who underwent open radical cystectomy on ERAS with any type of diversion. Robotic cases were excluded. Relevant demographics and clinical variables were collected and included post-operative patient-reported pain scores, oral morphine equivalents (OMEs) used, length of stay (LOS), and time to ambulation (TTA).
RESULTS: 82 patients were included: 30 received LB and 52 were historical controls. There were no statistically significant differences in the baseline patient demographics between the two cohorts (age, gender, race, marital status, opioid exposure prior to surgery, type of diversion, BMI). Mann-Whitney t-test revealed significant differences in LOS (5 vs 6 days, p [ 0.002), postoperative pain scores (0 vs 3, p [ 0.02), and OMEs received intraoperatively (62.3 vs 90.5 OME, p [ 0.04), in the PACU (6.9 vs 17.8 OME, p [ 0.04), and postoperative days 0-3 (6.0 vs 254.2 OME, p < 0.001). There was no statistically significant difference in the TTA (14 vs 12 hours, p [ 0.35). No adverse effects were reported.
